Core Viewpoint - The stock of Jia Shitang has shown a significant increase in price and trading activity, indicating potential investor interest despite recent declines in revenue and profit [1][2]. Group 1: Stock Performance - On November 14, Jia Shitang's stock rose by 2.01%, reaching 15.71 CNY per share, with a trading volume of 93.48 million CNY and a turnover rate of 2.06%, resulting in a total market capitalization of 4.583 billion CNY [1]. - Year-to-date, Jia Shitang's stock price has increased by 23.22%, with a 7.02% rise over the last five trading days, 16.20% over the last 20 days, and 8.27% over the last 60 days [1]. - The company has appeared on the "Dragon and Tiger List" once this year, with the most recent appearance on May 8, where it recorded a net buy of -534.52 million CNY [1]. Group 2: Financial Performance - For the period from January to September 2025, Jia Shitang reported operating revenue of 14.459 billion CNY, a year-on-year decrease of 21.80%, and a net profit attributable to shareholders of 141 million CNY, down 38.81% year-on-year [2]. - Cumulatively, Jia Shitang has distributed 874 million CNY in dividends since its A-share listing, with 216 million CNY distributed over the past three years [3]. Group 3: Company Overview - Jia Shitang Pharmaceutical Co., Ltd. is located in Haidian District, Beijing, and was established on April 22, 1997, with its shares listed on August 18, 2010. The company's main business involves pharmaceutical wholesale and retail [1]. - The company operates in the pharmaceutical and biological sector, specifically in pharmaceutical commerce and distribution, and is involved in various concept sectors including small-cap stocks, pharmaceutical e-commerce, and cold chain logistics [2].

Market Overview - The pharmaceutical commercial sector rose by 0.17% on November 13, with HeFu China leading the gains [1] - The Shanghai Composite Index closed at 4029.5, up 0.73%, while the Shenzhen Component Index closed at 13476.52, up 1.78% [1] Stock Performance - HeFu China (603122) closed at 22.10, with a 10.00% increase and a trading volume of 483,300 shares, amounting to a transaction value of 1.052 billion [1] - Renmin Tongtai (600829) also saw a 10.00% increase, closing at 13.75 with a trading volume of 69,400 shares [1] - Other notable performers included Yao Yi Gou (300937) with a 3.13% increase, closing at 36.21, and Bihe Pharmaceutical (002788) with a 2.51% increase, closing at 10.63 [1] Capital Flow - The pharmaceutical commercial sector experienced a net outflow of 269 million from institutional investors, while retail investors saw a net inflow of 305 million [2] - Notable stocks with significant capital flow included Jia Shi Tang (002462) with a net inflow of 20.71 million from institutional investors [2] - Daclin (603233) had a net outflow of 11.60 million from retail investors, indicating mixed investor sentiment [2]

Group 1 - The company, Jiashitang (002462.SZ), stated on the investor interaction platform that its business does not involve the Taiwan region of China [1]

Core Insights - The pharmaceutical commercial sector experienced a rise of 0.69% on November 3, with HeFu China leading the gains [1] - The Shanghai Composite Index closed at 3976.52, up 0.55%, while the Shenzhen Component Index closed at 13404.06, up 0.19% [1] Stock Performance Summary - HeFu China (603122) closed at 10.77, with a significant increase of 10.01% and a trading volume of 252,300 shares, amounting to a transaction value of 271 million [1] - Jianfa Zhixin (301584) saw a rise of 3.98%, closing at 33.67 with a trading volume of 143,300 shares [1] - Renmin Tongtai (600829) increased by 3.93%, closing at 8.99 with a trading volume of 337,500 shares [1] - Other notable performers include Jia Shitang (002462) with a 2.43% increase and Sai Li Medical (603716) with a 2.36% increase [1] Capital Flow Analysis - The pharmaceutical commercial sector experienced a net outflow of 78.21 million from institutional investors, while retail investors saw a net inflow of 94.46 million [2] - The top stocks by net inflow from retail investors include Renmin Tongtai (600829) with 17.00 million and Baiyang Pharmaceutical (301015) with 16.33 million [3] - Conversely, institutional investors showed a significant net inflow in Guoyao Yizhi (000028) with 15.04 million, indicating strong institutional interest [3]

嘉事堂药业股份有限公司 对外担保管理办法 （2025 年修订） 2025 年 10 月 27 日 北京 经公司 2025 年第四次临时股东会审议通过 | | | 第一章 总则 第一条 为规范嘉事堂药业股份有限公司（以下简称"公司"） 的对外担保行为，有效防范公司对外担保风险，保护投资者合法权益， 根据《中华人民共和国公司法》《中华人民共和国证券法》《中华人 民共和国民法典》等法律法规，中国证监会制定的《上市公司监管指 引第 8 号——上市公司资金往来、对外担保的监管要求》等规范性文 件，深圳证券交易所制定的《深圳证券交易所股票上市规则》等监管 规则，以及《嘉事堂药业股份有限公司章程》（以下简称《公司章程》） 等相关规定，特制定本办法。 第二条 本办法所称对外担保，指公司为他人提供的担保，包括 对控股子公司提供的担保。公司和控股子公司不得向合并报表范围之 外的主体提供担保，确有必要提供担保的，应一事一议，严格履行公 司治理程序。 对于具有实际权利义务，具备担保属性和可执行性的安慰函、支 持函、维好函、差额补足函、兜底函等类担保文件，视同担保，应严 格按照担保相关规定，履行公司治理程序。 第三条 本办法适用于公司 ...

2025 年 10 月 27 日 北京 经公司 2025 年第四次临时股东会审议通过 | 1 | 1 | | --- | --- | | | 4 | | | A | | | | 第一章 总则 第一条 为了加强对嘉事堂药业股份有限公司（以下简称"公 司"）募集资金行为的管理，规范募集资金的使用，切实保护广大投 资者的利益，根据《中华人民共和国公司法》《中华人民共和国证券 法》《上市公司证券发行注册管理办法》《上市公司募集资金监管规则》 嘉事堂药业股份有限公司 募集资金管理制度 （2025 年修订） 《深圳证券交易所股票上市规则》（以下简称《股票上市规则》），《深 圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范 运作》等有关法律、法规、规范性文件和《嘉事堂药业股份有限公司 章程》（以下简称《公司章程》）的要求，结合公司实际情况，特制定 本制度。 第二条 本制度所称募集资金是指公司通过发行股票或者其他 具有股权性质的证券，向投资者募集并用于特定用途的资金，不包括 公司为实施股权激励计划募集的资金。 本制度所称超募资金，是指实际募集资金净额超过计划募集资金 金额的部分。 第三条 公司制定募集资金计划时 ...

嘉事堂药业股份有限公司 分红管理制度 （2025 年修订） 2025 年 10 月 27 日 北京 经 2025 年第四次临时股东会审议通过 为进一步规范公司分红行为，推动公司建立科学、持续、稳定的 分红机制，保护中小投资者合法权益，根据《上市公司监管指引第 3 号——上市公司现金分红》《深圳证券交易所股票上市规则》《深圳证 券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》 以及《公司章程》的有关规定，结合公司实际情况，制定本制度。 第一节 公司分红政策 第一条 根据法律法规和《公司章程》，公司缴纳所得税后的利 润按下列顺序分配： （一）公司分配当年税后利润时，应当提取税后利润的 10%列入 公司法定公积金。公司法定公积金累计额为公司注册资本的 50%以上 的，可以不再提取。 （二）公司的法定公积金不足以弥补以前年度亏损的，在依照前 款规定提取法定公积金之前，应当先用当年利润弥补亏损。 公司持有的本公司股份不参与分配利润。 第二条 公司的公积金用于弥补公司的亏损、扩大公司生产经营 或者转为增加公司资本。 公积金弥补公司亏损，先使用任意公积金和法定公积金；仍不能 弥补的，可以按照规定使用资本公积 ...

关于嘉事堂药业股份有限公司 2025 年第四次临时股东会的法律意见书 文件编号：安理法意（2025）嘉字第 102701 号 致：嘉事堂药业股份有限公司 北京市安理律师事务所（以下简称"本所"）接受嘉事堂药业股份有限公司 （以下简称"嘉事堂"或"公司"）委托，指派张晓光律师、王瑞欣律师（以下 简称"承办律师"）担任嘉事堂药业股份有限公司于 2025 年 10 月 27 日召开的 2025 年第四次临时股东会（以下简称"本次股东会"）特别法律顾问，出席会 议，并出具本法律意见书。 本法律意见书系依据《中华人民共和国证券法》（以下简称"证券法"）、 《中华人民共和国公司法》（以下简称"公司法"）、中国证券监督管理委员会 《上市公司股东会规则》（以下简称"股东会规则"）、《深圳证券交易所股票 上市规则》等规范性文件及《嘉事堂药业股份有限公司章程》（以下简称"公司 章程"），并结合《嘉事堂药业股份有限公司第七届董事会第十九次临时会议决 议的公告》及《嘉事堂药业股份有限公司关于召开 2025 年第四次临时股东会的 通知公告》而出具。 第一节 律师声明 北京市安理律师事务所 1. 本法律意见书仅对出具日以前与本次股东会有 ...

证券代码：002462 证券简称：嘉事堂 公告编号：2025-55 嘉事堂药业股份有限公司 2025年第四次临时股东会决议公告 一、会议召开和出席情况 （一）嘉事堂2025年第四次临时股东会于2025年10月27日下午3点在公司二 楼会议室召开。会议由公司董事长徐曦先生主持，本次股东会按照会议议程，采 用现场表决与网络投票相结合的表决方式，审议了相关议案并作出决议。本次股 东会的召开符合《公司法》和《公司章程》的有关规定，会议召开合法有效。 （二）会议出席情况 1. 股东出席的总体情况： 通过现场和网络投票的股东155人，代表股份120,432,168股，占公司有表决 权股份总数的41.2853％。 本公司及董事会全体成员保证信息披露的内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 特别提示： 1．本次股东会未出现否决提案的情形。 2．本次股东会未涉及变更以往股东会已通过的决议。 （1）通过现场投票的股东7人，代表股份117,649,375股，占公司有表决权 股份总数的40.3313％。 （2）通过网络投票的股东148人，代表股份2,782,793股，占公司有表决权 股份总数的0.9540％。 ...

Core Viewpoint - The company, Jia Shi Tang, reported a significant decline in both revenue and net profit for the first three quarters of 2025, indicating ongoing challenges in its financial performance [1][2]. Financial Performance - For the first three quarters of 2025, the company achieved a revenue of 14.459 billion yuan, a year-on-year decrease of 21.80% [1]. - The net profit attributable to shareholders was 141 million yuan, down 38.81% year-on-year [1]. - In Q3 2025, revenue was 4.759 billion yuan, reflecting a 15.79% decline compared to the same period last year [1]. - The net profit for Q3 was approximately 34.07 million yuan, a decrease of 45.71% year-on-year [1]. - Total operating costs for the first three quarters fell to 14.061 billion yuan from 18.065 billion yuan in the previous year [1]. - The gross margin has been declining for five consecutive years, dropping from 10.23% in 2019 to 6.28% in the first three quarters of 2025 [1]. - The net profit margin also remained low, decreasing to 1.32% in the first three quarters of 2025 [1]. Market Performance - The company's stock price has seen a significant decline, with a recent price of 14.03 yuan per share, representing an 83.16% drop over the past decade [2]. - The market capitalization of Jia Shi Tang is currently 4.1 billion yuan [2]. Strategic Focus - The company is primarily engaged in pharmaceutical retail and wholesale, along with third-party logistics for pharmaceuticals [1]. - Jia Shi Tang is focusing on enhancing its core business in drug and medical device distribution, aiming to provide high-quality healthcare products and services [5]. - The company is also looking to leverage its supply chain value in the healthcare sector, aligning with the broader strategic goals of its controlling entity, China Everbright Group [5].